<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04175990</url>
  </required_header>
  <id_info>
    <org_study_id>UKMPPI/111/8/JEP-2018-165</org_study_id>
    <nct_id>NCT04175990</nct_id>
  </id_info>
  <brief_title>IVF Outcome Following Progestogen Ovarian Stimulation</brief_title>
  <official_title>Role Of Dydrogesterone Towards Oocyte and Embryo Quality in Polycystic Ovarian Syndrome (PCOS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University of Malaysia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National University of Malaysia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The new strategy is by using the progestogen to block the luteinizing hormone(LH) surge&#xD;
      either endogenous during luteal phase stimulation, or exogenous in the follicular phase i.e&#xD;
      progestin primed ovarian stimulation (PPOS). The goal of PPOS is to develop a single dominant&#xD;
      follicle. Various types of oral Progestin had been studied before including&#xD;
      Medroxyprogesterone Acetate (MPA) and Utrogestan with different dosage. A different study by&#xD;
      Wang et al conducted by using MPA to patients with PCOS. The use of MPA is contraindicated in&#xD;
      human pregnancy whereas Dydrogesterone had been extensively used worldwide for the treatment&#xD;
      of threatened miscarriage as well as luteal support in infertility setting. Previous protocol&#xD;
      on PPOS showed inconclusive results. Therefore in this study, Dydrogesterone was used as the&#xD;
      Progestin Primed Ovarian hyperstimulation to explore its effect on PCOS women IVF outcome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective controlled cohort study conducted at the Department of Medical Assisted&#xD;
      Conception (MAC) unit of the University Kebangsaan Malaysia Medical Centre (UKMMC). From May&#xD;
      2018 through May 2019, women with Polycystic Ovarian Syndrome (PCOS) undergoing&#xD;
      IVF/intracytoplasmic sperm insemination(ICSI) regimens for the treatment of infertility were&#xD;
      recruited.&#xD;
&#xD;
      Patients recruited will then be randomized accordingly using the randomizer software. Group A&#xD;
      will be the interventional group and group B will be the control group.&#xD;
&#xD;
      Oocyte retrieval will be performed 34-36 hours following the human chorionic gonadotrophin&#xD;
      (hCG) trigger. Sperm was obtained on the same day. Mature oocytes will be fertilized with&#xD;
      sperm via IVF or ICSI. Fertilized embryos were observed via time laps method and the progress&#xD;
      and cleavage were monitored before planning for embryo transfer. Embryo transfer will be&#xD;
      performed on day 3 or day 5 after oocyte retrieval.&#xD;
&#xD;
      All results will be analyzed using Statistical Package for the Social Sciences(SPSS) version&#xD;
      21 software. Descriptive analysis will be done for demographic data and presented in mean ±&#xD;
      Standard deviation (SD). Demographic characteristic between the two groups will be compared&#xD;
      with the use of the Mann-Whitney U test. The categorical data was analysed by using&#xD;
      Chi-square test for the association of variables. A p-value of 0.05 or less was considered to&#xD;
      be significant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 10, 2018</start_date>
  <completion_date type="Actual">May 9, 2019</completion_date>
  <primary_completion_date type="Actual">March 10, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of oocyte retrieval</measure>
    <time_frame>30 hour after trigger with HCG 10000 International unit (IU)</time_frame>
    <description>number of oocyte retrieved</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biochemical pregnancy rate</measure>
    <time_frame>14 days after embryo transferred</time_frame>
    <description>serum Bhcg more than 5 mol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>clinical pregnancy rate</measure>
    <time_frame>4 weeks after embryo transfer</time_frame>
    <description>presence of intrauterine gestational sac</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">155</enrollment>
  <condition>IVF</condition>
  <condition>Oocyte Maturation Defect 1</condition>
  <condition>Clinical Pregnancy Rate</condition>
  <condition>Ovarian Hyperstimulation</condition>
  <arm_group>
    <arm_group_label>Progestogen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Dydrogesterone 10mg tds was given from day 1 of menses till day of trigger</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard combine minimal stimulation protocol</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Oral clomiphene citrate 100mg daily given from day 1 till day 10 of menses with additional gonadotrophin (Menopur 225mg daily) from day 3 of menses till trigger day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dydrogesterone Pill</intervention_name>
    <description>started from day 1 of menses till trigger day</description>
    <arm_group_label>Progestogen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  · Aged 20 - 40 years old&#xD;
&#xD;
               -  Basal serum follicular stimulating hormone(FSH) level of no more than 10 IU/L&#xD;
&#xD;
               -  Diagnosis of PCOS met using Rotterdam criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  low AMH level (AMH less than 3 ng/ml).&#xD;
&#xD;
               -  Contraindicated to ovarian stimulation treatment eg: history of severe ovarian&#xD;
                  hyper stimulation syndrome(OHSS)&#xD;
&#xD;
               -  Presence of uterine pathology eg: adenomyosis, large uterine fibroid.&#xD;
&#xD;
               -  Patients who has had poor ovarian stimulation of twice or more.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muhammad azrai abu, medical Degree</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Obstetrics and Gynecology, UKM Medical Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medically Assisted Conception Unit, Ukm Medical Centre</name>
      <address>
        <city>Cheras</city>
        <state>Kuala Lumpur</state>
        <zip>56000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <reference>
    <citation>7. Neill JD. Knobil and Neill's physiology of reproduction. 3rd edition. San Diego, CA: Elsevier, 2006: 1289-301</citation>
  </reference>
  <results_reference>
    <citation>Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016 Jul;106(1):6-15. doi: 10.1016/j.fertnstert.2016.05.003. Epub 2016 May 24. Review.</citation>
    <PMID>27233760</PMID>
  </results_reference>
  <results_reference>
    <citation>Boomsma CM, Fauser BC, Macklon NS. Pregnancy complications in women with polycystic ovary syndrome. Semin Reprod Med. 2008 Jan;26(1):72-84. doi: 10.1055/s-2007-992927. Review.</citation>
    <PMID>18181085</PMID>
  </results_reference>
  <results_reference>
    <citation>Sam S, Dunaif A. Polycystic ovary syndrome: syndrome XX? Trends Endocrinol Metab. 2003 Oct;14(8):365-70. Review.</citation>
    <PMID>14516934</PMID>
  </results_reference>
  <results_reference>
    <citation>Shah DK, Missmer SA, Berry KF, Racowsky C, Ginsburg ES. Effect of obesity on oocyte and embryo quality in women undergoing in vitro fertilization. Obstet Gynecol. 2011 Jul;118(1):63-70. doi: 10.1097/AOG.0b013e31821fd360.</citation>
    <PMID>21691164</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhu X, Ye H, Fu Y. The Utrogestan and hMG protocol in patients with polycystic ovarian syndrome undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments. Medicine (Baltimore). 2016 Jul;95(28):e4193. doi: 10.1097/MD.0000000000004193.</citation>
    <PMID>27428219</PMID>
  </results_reference>
  <results_reference>
    <citation>Al-Inany HG, Youssef MA, Ayeleke RO, Brown J, Lam WS, Broekmans FJ. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2016 Apr 29;4:CD001750. doi: 10.1002/14651858.CD001750.pub4. Review.</citation>
    <PMID>27126581</PMID>
  </results_reference>
  <results_reference>
    <citation>van der Spuy ZM, Dyer SJ. The pathogenesis of infertility and early pregnancy loss in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004 Oct;18(5):755-71. Review.</citation>
    <PMID>15380145</PMID>
  </results_reference>
  <results_reference>
    <citation>Bosch E, Valencia I, Escudero E, Crespo J, Simón C, Remohí J, Pellicer A. Premature luteinization during gonadotropin-releasing hormone antagonist cycles and its relationship with in vitro fertilization outcome. Fertil Steril. 2003 Dec;80(6):1444-9.</citation>
    <PMID>14667881</PMID>
  </results_reference>
  <results_reference>
    <citation>Kuang Y, Chen Q, Fu Y, Wang Y, Hong Q, Lyu Q, Ai A, Shoham Z. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 2015 Jul;104(1):62-70.e3. doi: 10.1016/j.fertnstert.2015.03.022. Epub 2015 May 5.</citation>
    <PMID>25956370</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang Y, Chen Q, Wang N, Chen H, Lyu Q, Kuang Y. Controlled Ovarian Stimulation Using Medroxyprogesterone Acetate and hMG in Patients With Polycystic Ovary Syndrome Treated for IVF: A Double-Blind Randomized Crossover Clinical Trial. Medicine (Baltimore). 2016 Mar;95(9):e2939. doi: 10.1097/MD.0000000000002939.</citation>
    <PMID>26945402</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhu X, Zhang X, Fu Y. Utrogestan as an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Medicine (Baltimore). 2015 May;94(21):e909. doi: 10.1097/MD.0000000000000909.</citation>
    <PMID>26020402</PMID>
  </results_reference>
  <results_reference>
    <citation>McCartney CR, Marshall JC. CLINICAL PRACTICE. Polycystic Ovary Syndrome. N Engl J Med. 2016 Jul 7;375(1):54-64. doi: 10.1056/NEJMcp1514916. Review.</citation>
    <PMID>27406348</PMID>
  </results_reference>
  <results_reference>
    <citation>Diamond MP, Kruger M, Santoro N, Zhang H, Casson P, Schlaff W, Coutifaris C, Brzyski R, Christman G, Carr BR, McGovern PG, Cataldo NA, Steinkampf MP, Gosman GG, Nestler JE, Carson S, Myers EE, Eisenberg E, Legro RS; Eunice Kennedy Shriver National Institute of Child Health and Human Development Cooperative Reproductive Medicine Network. Endometrial shedding effect on conception and live birth in women with polycystic ovary syndrome. Obstet Gynecol. 2012 May;119(5):902-8. doi: 10.1097/AOG.0b013e31824da35c.</citation>
    <PMID>22525900</PMID>
  </results_reference>
  <results_reference>
    <citation>Wei D, Shi Y, Li J, Wang Z, Zhang L, Sun Y, Zhou H, Xu Y, Wu C, Liu L, Wu Q, Zhuang L, Du Y, Li W, Zhang H, Legro RS, Chen ZJ. Effect of pretreatment with oral contraceptives and progestins on IVF outcomes in women with polycystic ovary syndrome. Hum Reprod. 2017 Feb;32(2):354-361. doi: 10.1093/humrep/dew325. Epub 2016 Dec 19.</citation>
    <PMID>27999118</PMID>
  </results_reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 20, 2019</study_first_submitted>
  <study_first_submitted_qc>November 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2019</study_first_posted>
  <last_update_submitted>November 22, 2019</last_update_submitted>
  <last_update_submitted_qc>November 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National University of Malaysia</investigator_affiliation>
    <investigator_full_name>Azrai Abu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>progestogen</keyword>
  <keyword>ovarian stimulation regime</keyword>
  <keyword>IVF outcome</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dydrogesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

